SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:
Summary FMB WEALTH MANAGEMENT initiated a new position in AnaptysBio Inc(ANAB), purchasing 5,592 shares valued at approximately $271,100 as of its late
Campbell and CO Investment Adviser LLC bought a new stake in AnaptysBio, Inc. (NASDAQ: ANAB) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 18,281 shares of the biotechnology company's stock, valued at approximately $560,000. Campbell and CO Investment
AnaptysBio, Inc. (ANAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
An AnaptysBio director sold 3,900 shares of the stock on Dec. 23 for a total value of $193,342.50. The sale represented 28.82% of J.
The chief medical officer of AnaptysBio sold 3,650 shares for $163,191.50 on Thursday. The transaction represented 8.0% of Paul Lizzul's direct common stock holdings, reducing his direct stake from 45,738 to 42,088 shares, as reported.
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) insider Paul Lizzul sold 3,650 shares of the company's stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $44.71, for a total value of $163,191.50. Following the completion of the transaction, the insider owned 42,088 shares of the company's stock,
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) CEO Daniel Faga sold 14,281 shares of the company's stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $44.71, for a total value of $638,503.51. Following the transaction, the chief executive officer directly owned 479,344 shares of the
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) insider Eric Loumeau sold 9,639 shares of the business's stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $45.56, for a total transaction of $439,152.84. Following the completion of the transaction, the insider owned 9,157 shares in the company, valued
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) CEO Daniel Faga sold 9,202 shares of the firm's stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $45.11, for a total value of $415,102.22. Following the transaction, the chief executive officer owned 466,787 shares in the company, valued at
